SD: Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
Published on May 29, 2018
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM SD
Specialized Disclosure Report
ResMed Inc.
(Exact Name of Registrant as Specified in Charter)
| Delaware | 001-15317 | 98-0152841 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
9001 Spectrum Center Blvd.
San Diego, California 92123
(Address of Principal Executive Offices)
David Pendarvis
(858) 836-5000
(Name and telephone number, including area code, of the person to contact in connection with this report.)
Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
| ☒ | Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2017. |
Section 1 - Conflict Minerals Disclosure
Item 1.01 and Item 1.02 Conflict Minerals Disclosure and Report, Exhibits
Conflict Minerals Disclosure
This Form SD of ResMed Inc. is filed in accordance with Exchange Act Rule 13p-1, and covers the reporting period from January 1, 2017 through December 31, 2017.
The description of our reasonable country of origin inquiry process, the results of our inquiry, and the determination we reached as a result of our reasonable country of origin inquiry process is included in our conflict minerals report attached as an exhibit to this Form SD. A copy of our conflict minerals report for the reporting period January 1, 2017 to December 31, 2017 is provided as Exhibit 1.01 and is available at www.resmed.com> For Investors > Board and Management > Corporate Governance.
Section 2 Exhibits
Item 2.01 Exhibits
The following exhibit is filed as part of this report.
Exhibit 1.01 Conflict Minerals Report for the reporting period January 1, 2017 to December 31, 2017.
2
SIGNATURES
We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.
| RESMED INC. (registrant) |
||||||
| Date: May 29, 2018 | By: | /s/ David Pendarvis | ||||
| Name: | David Pendarvis | |||||
| Its: | Chief administrative officer, global general counsel and secretary | |||||
EXHIBIT INDEX
| Exhibits: |
Description of Document |
|
| 1.01 | Conflict Minerals Report for the reporting period January 1, 2017 to December 31, 2017. | |